Managers / Q4 2024
Alerce Investment Management, L.P.
CIK 0001844002 · 676 N. MICHIGAN AVENUE, SUITE 4000, CHICAGO, IL, 60611 · (312) 448-5500
Summary
Alerce Investment Management, L.P. reported $57M in U.S.-listed holdings across 5 positions for Q4 2024.
The portfolio is heavily concentrated: ANNX alone accounts for 66.9% of reported value.
The book was largely unchanged from Q3 2024.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 92.8% · $53M
- ADR · 7.2% · $4M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| VRNAVERONA PHARMA PLC | TRIMMED | −117.9K | 88.0K | −$2M | $4M |
| ANNXANNEXON INC | HELD | +0 | 7.41M | −$6M | $38M |
| AKBAAKEBIA THERAPEUTICS INC | HELD | +0 | 5.75M | +$3M | $11M |
| AMWLAMERICAN WELL CORP | HELD | +0 | 523.8K | −$1M | $4M |
| WHWKAADI BIOSCIENCE INC | HELD | +0 | 659 | +$721 | $2,079 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ANNXANNEXON INChistory → | COM | 66.89% | $38M | 7.41M |
| 2 | AKBAAKEBIA THERAPEUTICS INChistory → | COM | 19.23% | $11M | 5.75M |
| 3 | VRNAVERONA PHARMA PLChistory → | SPONSORED ADS | 7.19% | $4M | 88.0K |
| 4 | AMWLAMERICAN WELL CORPhistory → | COM CL A NEW | 6.69% | $4M | 523.8K |
| 5 | WHWKAADI BIOSCIENCE INC | COM | 0.00% | $2,079 | 659 |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2024 | $57M | 5 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $62M | 5 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $51M | 5 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $95M | 5 | May 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $75M | 5 | Feb 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $59M | 6 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $77M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $76M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $87M | 6 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $104M | 7 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $54M | 7 | Aug 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $59M | 7 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $98M | 7 | Feb 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $146M | 7 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $184M | 7 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $226M | 7 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $254M | 7 | Feb 11, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.